Novartis International AG said it is stopping work on albinterferon alfa-2b for hepatitis C and Mycograb (efungumab) for fungal infections in order to focus on more promising products. It will take a charge of $590 million in the third quarter. ---Subscribe to MedNous to access this article--- Company News Research & University News
